Sciverse and Bhat Biotech forge strategic collaboration for next-gen molecular diagnostics

Pune-based Sciverse Solutions, an artificial intelligence (AI)-first Point-of-Care Testing (PoCT) diagnostics company, has announced its strategic collaboration with Bengaluru-based Bhat Biotech, a leading Indian biotechnology and molecular diagnostics company. The partnership will focus on co-developing next-generation molecular diagnostic platforms designed to make testing faster, smarter, and more accessible at the point of care.

This collaboration combines Sciverse’s deep expertise in AI, biosensors, microfluidics, and hardware design with Bhat Biotech’s proven capabilities in molecular assay development and manufacturing. Together, both organisations aim to accelerate the development of portable, high-accuracy diagnostic systems capable of delivering lab-quality results in real time — directly at the site of patient care.

“Molecular diagnostics is shaping the future of healthcare — enabling faster, more precise, and accessible disease detection,” said Rahul Singh, Managing Director of Sciverse Solutions. “Our collaboration with Bhat Biotech reflects a shared commitment to redefining how molecular testing can be brought closer to patients, doctors, and healthcare workers everywhere.”

Dr Shama Bhat, Founder of Bhat Biotech added, “By integrating Bhat Biotech’s assay chemistry expertise with Sciverse’s device and AI capabilities, we are confident this collaboration will lead to molecular platforms that are more robust, cost-effective, and scalable across global markets.”